MARKET

ERAS

ERAS

Erasca, Inc.
NASDAQ
1.330
-0.060
-4.32%
After Hours: 1.331 +0.001 +0.05% 16:37 05/13 EDT
OPEN
1.420
PREV CLOSE
1.390
HIGH
1.420
LOW
1.330
VOLUME
868.21K
TURNOVER
--
52 WEEK HIGH
3.450
52 WEEK LOW
1.010
MARKET CAP
376.77M
P/E (TTM)
-1.9236
1D
5D
1M
3M
1Y
5Y
1D
Erasca reports Q1 EPS (11c), consensus (13c)
TipRanks · 11h ago
Erasca Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters · 11h ago
Erasca Inc <ERAS.OQ> expected to post a loss of 13 cents a share - Earnings Preview
Reuters · 11h ago
Erasca Q1 EPS $(0.11) Beats $(0.12) Estimate
Benzinga · 12h ago
Press Release: Erasca Reports First Quarter 2025 Business Updates and Financial Results
Dow Jones · 12h ago
Erasca announces IND clearance, prioritizing of RAS-targeting franchise
TipRanks · 20h ago
ERASCA INC: PHASE 1 MONOTHERAPY DATA FOR ERAS-0015 & ERAS-4001 EXPECTED IN 2026
Reuters · 20h ago
Weekly Report: what happened at ERAS last week (0505-0509)?
Weekly Report · 1d ago
More
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.

Webull offers Erasca Inc stock information, including NASDAQ: ERAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ERAS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ERAS stock methods without spending real money on the virtual paper trading platform.